Abstract
The main objective of the present study was to estimate the levels of soluble CD44 in cervical cancer patients by determining whether it consistently discriminates the carcinoma of the cervix from early or premalignant stage of the cervical cancer. Serum concentrations of sCD44s in cervical cancer patients were determined by an enzyme-linked immunosorbent assay from serum of 50 cases of cervical cancer patients and 50 cases of suspected patients with premalignant disease of cervical intraepithelial neoplasia. The sensitivity and specificity of the test for differentiating carcinoma of the cervix from premalignant stage were evaluated by plotting receiver operating characteristic (ROC) curve. Significant increase in the levels of soluble CD44 was observed in cervical cancer patients (664.80 ± 26.58 ng/ml), when compared to healthy (P < 0.001) and suspected (P < 0.05) or premalignant cases (275.19 ± 24.39 and 514.33 ± 54.57 ng/ml, respectively). High-grade squamous intraepithelial lesions, adenocarcinoma in situ and premalignance with dysplasia show significant (P < 0.001) increase in the concentration of soluble CD44 levels when compared to other types. A ROC curve was plotted and estimated the threshold value as 633.11 ng/ml. In conclusion, the data indicated an up-regulation of soluble CD44 protein which detect and differentiates the cervical carcinoma from premalignant cases with 62.6 % sensitivity.
Similar content being viewed by others
References
Garnett GP, Kim JJ, French K, Goldie SJ. Modeling the impact of HPV vaccines on cervical cancer and screening programmes. Vaccine. 2006;24:S178–86.
Zheng GX, Wang CX, Qu X, Den XM, Deng BP, Zhang J. Establishment of serum protein pattern for screening colorectal cancer using SELDI-TOF-MS. Exp Oncol. 2006;28(4):282–7.
Wulfkuhle JD, Liotta LA, Petricoin EF. Proteomic applications for the early detection of cancer. Nat Rev Cancer. 2003;3:267–75.
Givehchian M, Woerner SM, Lacroix J, Zöller M, Drings P, Becker H, et al. Expression of CD44 splice variants in normal respiratory epithelium and 11 bronchial carcinomas: no evidence for altered CD44 splicing in metastasis. Oncogene. 1996;12:1137–44.
Higashikawa K, Yokozaki H, Ue T, Taniyama K, Ishikawa T, Tarin D, Tahara E. Evaluation of CD44 transcription variants in human digestive tract carcinomas and normal tissues. Int J Cancer. 1996;66:11–7.
De Rossi G, Marroni P, Paganuzzi M, Mauro FR, Tenca C, Zarcone D, Velardi A, Molica S, Grossi CE. Increased serum levels of soluble CD44 standard, but not of variant isoforms v5 and v6, in B cell chronic lymphocytic leukemia. Leukemia. 1997;11:134–41.
Ermak G, Jennings T, Robinson L, Ross JS, Figge J. Restricted patterns of CD44 variant expression in human papillary thyroid carcinoma. Cancer Res. 1996;56:1037–42.
Sliutz G, Tempfer C, Winkler S, Kohlberger P, Reinthaller A, Kainz C. Immunohistochemical and serological evaluation of CD44 splice variants in human ovarian cancer. Br J Cancer. 1995;72:1494–7.
Jalknen S, Joensuu H, Soderstroom KO, Klemi P. Lymphocyte homing and clinical behavior of non-Hodgkin’s lymphoma. J clin Invest. 1991;87:1835–40.
Terpe HJ, Stark H, Prehm P, Gunthert U. CD44 variant isoforms are preferentially expressed in basal epithelial of non-malignant human fetal and adult tissues. Histochemistry. 1994;101:79–89.
Miyake K, Underhill CB, Lesley J, Kincade PW. Hyaluronate can function as a cell adhesion molecule and CD44 participates in hyluronate recognistion. J Exp Med. 1990;172:69–75.
Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at 12 alternatively spliced exons. Proc Natl Acad Sci. 1992;89:12160–4.
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57–70.
Mulder JWR, Kruyt PM, Sewnath M, Seldernrijk CA, Weidema WF, Offerhaus GJA, Pals ST. Colorectal Cancer prognosis and expression of exon v6-containing CD44 proteins. Lancet. 1994;344:1470–2.
Guo YJ, Liu G, Wang X, Jin D, Wu M, Ma J, Sy MS. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res. 1994;54:422–6.
Sinn HP, Heider KH, Skroch-Angel P, von Minckwitz G, Kaufmann M, Herrlich P, Ponta H. Human mammary carcinomas express homologues of rat metastasis-associated variants of CD44. Breast Cancer Res Treat. 1995;36:307–13.
Ueda J, Kajita M, Suenaga N, Fujii K, Seiki M. Sequence-specific silencing of MT1-MMP expression suppresses tumor cell migration and invasion: importance of MT1-MMP as a therapeutic target for invasive tumors. Oncogene. 2003;22:8716–22.
Vishnu Vardhan R, Sarma KVS. Determining the optimal cut of point in an ROC curve: a spreadsheet approach. Inter J Stat Analysis. 2012;2(3):219–25.
Kainz C, Kohlberger P, Sliutz G. Splice variants of cd44 in human cervical cancer stage Ib to IIb. Gynecol Oncol. 1995;57:383–7.
Kainz C, Kohlberger P, Tempfer C, Sliutz G, Gitsch G. Prognostic value of CD44 splice variants in human cervical cancer stage III. Eur J Cancer. 1995;31:1706–9.
Dall P, Heider KH, Sinn HP, Skroch-Angel P, Adolf G. Comparison of immunohistochemistry and RT-PCR for detection of CD44v-expression, a new prognostic factor in human breast cancer. Int J Cancer. 1995;60:471–7.
Ioachim E, Assimakopoulos D, Goussia AC, Peschos D, Skevas A, Agnantis NJ. Glycoprotein CD44 expression in benign, premalignant and malignant epithelial lesions of the larynx: an immunohistochemical study including correlation with Rb, p53, Ki-67 and PCNA. Histol Histopathol. 1999;14(4):1113–8.
Nanda K, McCrory DC, Myers ER. Accuracy of the papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematicic review. Ann Intern Med. 2000;132:810–9.
Acknowledgments
The first author extends his thanks to UGC-Non-SAP (BSR), New Delhi fellowship for giving financial assistance and also thanks to Prof. Raju Naidu, Department of Radiation Oncology, Government General Hospital, Guntur, Andhra Pradesh, for providing pre- and posttreated cervical cancer samples.
Conflict of interest
The authors declare that there is no conflict of interests regarding the publication of this article.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Dasari, S., Rajendra, W. & Valluru, L. Evaluation of soluble CD44 protein marker to distinguish the premalignant and malignant carcinoma cases in cervical cancer patients. Med Oncol 31, 139 (2014). https://doi.org/10.1007/s12032-014-0139-9
Received:
Accepted:
Published:
DOI: https://doi.org/10.1007/s12032-014-0139-9